Financial reports
ARS
2023 FY
Annual report to shareholders
21 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
23 Mar 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
Current reports
8-K
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
29 Feb 24
8-K
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
9 Jan 24
8-K
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
8 Nov 23
8-K
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults
20 Sep 23
8-K
Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
2 Aug 23
8-K
Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
10 May 23
8-K
Departure of Directors or Certain Officers
5 May 23
8-K
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance
23 Feb 23
8-K
Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program
10 Jan 23
8-K
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
29 Dec 22
Registration and prospectus
S-8
Registration of securities for employees
22 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
6 May 22
S-8
Registration of securities for employees
6 May 22
S-3ASR
Automatic shelf registration
27 Aug 21
8-A12B/A
Registration of securities on exchange (amended)
12 Feb 21
S-8
Registration of securities for employees
6 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 19
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 19
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 19
Proxies
DEFA14A
Additional proxy soliciting materials
21 Mar 24
DEF 14A
Definitive proxy
21 Mar 24
DEFA14A
Additional proxy soliciting materials
23 Mar 23
DEF 14A
Definitive proxy
23 Mar 23
DEFA14A
Additional proxy soliciting materials
17 Mar 22
DEF 14A
Definitive proxy
17 Mar 22
DEFA14A
Additional proxy soliciting materials
19 Mar 21
DEF 14A
Definitive proxy
19 Mar 21
DEFA14A
Additional proxy soliciting materials
10 Apr 20
DEF 14A
Definitive proxy
20 Mar 20
Other
CT ORDER
Confidential treatment order
19 Jan 22
SEC STAFF
SEC staff action: Order
19 Nov 19
UPLOAD
Letter from SEC
19 Nov 19
CORRESP
Correspondence with SEC
13 Nov 19
UPLOAD
Letter from SEC
5 Nov 19
SEC STAFF
SEC staff action: Order
4 Nov 19
CT ORDER
Confidential treatment order
28 Nov 18
EFFECT
Notice of effectiveness
28 Aug 18
UPLOAD
Letter from SEC
28 Aug 18
CORRESP
Correspondence with SEC
24 Aug 18
Ownership
4
Dominick Colangelo
19 Apr 24
144
Notice of proposed sale of securities
18 Apr 24
144
Notice of proposed sale of securities
17 Apr 24
4
Alan L Rubino
11 Apr 24
4
ROBERT L MD ZERBE
29 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
4
Dominick Colangelo
15 Mar 24
4/A
Sean C. Flynn
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
144
Notice of proposed sale of securities
13 Mar 24